Die Anwendung von niedermolekularen Heparinen in der Schwangerschaft

Autor: W. Schramm, J. Harenberg, G. F. V. Tempelhoff, L Heilmann, Werner Rath, H. K. Breddin
Rok vydání: 2001
Předmět:
Zdroj: Geburtshilfe und Frauenheilkunde. 61:355-363
ISSN: 1438-8804
0016-5751
Popis: Anticoagulant therapy for thromboprophylaxis in pregnancy usually consists of non-fractionated heparin (UFH) in a dose of 10,000 IU twice daily or of low molecular weight heparin (LMWH). The potential advantages of LMWH are based on the plasma half-life and on their 90 - 95% bioavailability after s.c. administration. The complication rate of a pooled evaluation of patients treated during pregnancy with LMWH was 3.4% for vaginal bleeding, 1.7% for deep vein thrombosis, 3% for spontaneous abortion, 0.1% for osteoporotic fracture and 0.05% for HIT II. Management of patients with hereditary hypercoagulable state in pregnancy is controversial because of the scarcity of data to guide decision making and because of inconsistencies among the available data. The working group of GTH thrombophilia in pregnancy recommended guidelines for the management of women who receive antithrombotic therapy for prophylaxis of venous thrombosis and pregnancy complications. Low-risk patients receiving post partum antithrombotic therapy, women with moderate risk LMWH from the first diagnosis of the pregnancy and patients with higher risk received therapeutic doses of LMWH. Patients with antiphospholipid antibody syndrome (APS) are associated with a high rate of adverse pregnancy complications and should be referred to a unit that specializes in the management of acquired thrombophilia in pregnancy.
Databáze: OpenAIRE